Adaptive Biotechnologies Corporation (ADPT) DCF Valuation
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Adaptive Biotechnologies Corporation (ADPT) Bundle
Looking to assess the intrinsic value of Adaptive Biotechnologies Corporation? Our ADPT DCF Calculator integrates real-world data with comprehensive customization options, enabling you to refine your forecasts and enhance your investment choices.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 85.1 | 98.4 | 154.3 | 185.3 | 170.3 | 206.2 | 249.8 | 302.6 | 366.4 | 443.8 |
| Revenue Growth, % | 0 | 15.65 | 56.88 | 20.06 | -8.11 | 21.12 | 21.12 | 21.12 | 21.12 | 21.12 |
| EBITDA | -70.6 | -144.3 | -193.3 | -168.0 | -189.3 | -195.4 | -236.6 | -286.6 | -347.1 | -420.4 |
| EBITDA, % | -82.99 | -146.72 | -125.27 | -90.65 | -111.16 | -94.73 | -94.73 | -94.73 | -94.73 | -94.73 |
| Depreciation | 7.8 | 11.7 | 21.0 | 28.1 | 22.2 | 26.0 | 31.4 | 38.1 | 46.1 | 55.9 |
| Depreciation, % | 9.16 | 11.93 | 13.59 | 15.19 | 13.06 | 12.59 | 12.59 | 12.59 | 12.59 | 12.59 |
| EBIT | -78.4 | -156.1 | -214.3 | -196.1 | -211.5 | -203.0 | -245.9 | -297.8 | -360.7 | -436.9 |
| EBIT, % | -92.15 | -158.65 | -138.86 | -105.84 | -124.21 | -98.43 | -98.43 | -98.43 | -98.43 | -98.43 |
| Total Cash | 576.9 | 688.3 | 353.1 | 498.2 | 346.4 | 206.2 | 249.8 | 302.6 | 366.4 | 443.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 12.7 | 10.0 | 17.4 | 40.1 | 38.0 | 33.1 | 40.1 | 48.6 | 58.9 | 71.3 |
| Account Receivables, % | 14.9 | 10.21 | 11.28 | 21.62 | 22.3 | 16.06 | 16.06 | 16.06 | 16.06 | 16.06 |
| Inventories | 9.1 | 14.1 | 19.3 | 14.5 | 14.4 | 22.2 | 26.8 | 32.5 | 39.4 | 47.7 |
| Inventories, % | 10.66 | 14.29 | 12.48 | 7.8 | 8.49 | 10.74 | 10.74 | 10.74 | 10.74 | 10.74 |
| Accounts Payable | 4.5 | 3.2 | 3.3 | 8.1 | 7.7 | 8.1 | 9.8 | 11.8 | 14.3 | 17.4 |
| Accounts Payable, % | 5.23 | 3.29 | 2.14 | 4.36 | 4.53 | 3.91 | 3.91 | 3.91 | 3.91 | 3.91 |
| Capital Expenditure | -11.2 | -18.8 | -61.7 | -16.3 | -10.7 | -36.0 | -43.7 | -52.9 | -64.0 | -77.6 |
| Capital Expenditure, % | -13.17 | -19.11 | -40.01 | -8.82 | -6.28 | -17.48 | -17.48 | -17.48 | -17.48 | -17.48 |
| Tax Rate, % | 0.02396762 | 0.02396762 | 0.02396762 | 0.02396762 | 0.02396762 | 0.02396762 | 0.02396762 | 0.02396762 | 0.02396762 | 0.02396762 |
| EBITAT | -67.2 | -149.0 | -212.6 | -139.5 | -211.5 | -183.3 | -222.0 | -268.9 | -325.7 | -394.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -87.9 | -159.7 | -265.8 | -140.7 | -198.2 | -195.9 | -244.2 | -295.8 | -358.3 | -433.9 |
| WACC, % | 10.04 | 10.16 | 10.21 | 9.87 | 10.22 | 10.1 | 10.1 | 10.1 | 10.1 | 10.1 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,113.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -443 | |||||||||
| Terminal Value | -5,464 | |||||||||
| Present Terminal Value | -3,377 | |||||||||
| Enterprise Value | -4,490 | |||||||||
| Net Debt | 164 | |||||||||
| Equity Value | -4,655 | |||||||||
| Diluted Shares Outstanding, MM | 144 | |||||||||
| Equity Value Per Share | -32.24 |
What You Will Receive
- Flexible Forecast Inputs: Adjust key assumptions (growth %, margins, WACC) effortlessly to explore various scenarios.
- Comprehensive Data: Adaptive Biotechnologies Corporation's (ADPT) financial data pre-loaded to facilitate your analysis.
- Automated DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Tailored and Professional: A refined Excel model that meets your specific valuation requirements.
- Designed for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- Comprehensive DCF Calculator: Features in-depth unlevered and levered DCF valuation models tailored for Adaptive Biotechnologies Corporation (ADPT).
- WACC Calculator: Ready-to-use Weighted Average Cost of Capital sheet with adjustable parameters.
- Customizable Forecast Assumptions: Easily adjust growth rates, capital expenditures, and discount rates to fit your analysis.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specific to Adaptive Biotechnologies Corporation (ADPT).
- Interactive Dashboard and Charts: Visual representations provide a summary of essential valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Adaptive Biotechnologies Corporation’s (ADPT) pre-filled financial data and forecasts.
- Step 3: Modify critical inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Watch the DCF model update instantly as you adjust your assumptions.
- Step 5: Analyze the outputs and utilize the results for your investment decisions.
Why Choose Adaptive Biotechnologies Corporation (ADPT)?
- Innovative Solutions: Cutting-edge technology for advanced immune profiling.
- Data-Driven Insights: Leverage comprehensive data for informed decision-making.
- Customizable Services: Tailor our offerings to meet your specific research needs.
- Clear Communication: User-friendly reports and visuals facilitate understanding.
- Backed by Expertise: Supported by a team of industry leaders and researchers.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and trustworthy valuation models for portfolio assessments related to Adaptive Biotechnologies Corporation (ADPT).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation insights to clients focusing on Adaptive Biotechnologies Corporation (ADPT).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotech companies like Adaptive Biotechnologies Corporation (ADPT) are valued in the market.
What the Template Contains
- Pre-Filled Data: Includes Adaptive Biotechnologies Corporation’s historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model featuring automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on user-defined inputs.
- Key Financial Ratios: Evaluate Adaptive Biotechnologies Corporation’s profitability, efficiency, and leverage.
- Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
- Clear Dashboard: Visuals and tables summarizing essential valuation outcomes.